|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplementary Table S1.** Antibodies in immunohistochemical analysis. | | | | |
| Protein | Antibody | Company | | Threshold for overexpression  (Intensity and % expression in tumor) |
| TS | TS106/4H4B1 | | Invitrogen | ≥ 1+ and ≥10% |
| ERCC1 | 8F1 | | Abcam | ≥ 3+ and ≥10% or ≥2+ and ≥50% |
| TOPO1 | 1D6 | | Leica Biosystems | ≥ 2+ and ≥ 30% |
| PTEN | 6H2.1 | | Dako | ≥ 1+ and >50% |
| MGMT | M23.2 | | Invitrogen | ≥ 1+ and >35% |
| PD-L1 | SP142 | | BD Pharmingen and R&D Systems | ≥ 2+ and ≥ 5% |
| Abbreviations: ERCC1, excision repair cross-complementation group 1; MGMT, o(6)-methylguanine-methyltransferase; PD-L1, programmed death-ligand 1; PTEN, phosophatase and tensin homolog; TOPO1, topoisomerases 1; TS, thymidylase synthase. | | | | |